A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer

Inclusion Criteria: * Women ≥ 18 years of age * Have a clinical diagnosis of endocrine therapy induced alopecia (EIA) for breast cancer: * Selective estrogen receptor modulators (tamoxifen, toremifene) * Aromatase inhibitors (anastrozole, letrozole, exemestane) * Gonadotropin-releasing hormone agonist (leuprolide) OR * Must have a clinical diagnosis of chemotherapy induced (pCIA) alopecia with incomplete or absent regrowth of hair \> 3 months after completion of chemotherapy without use of endocrine cancer-related therapy (ET) within the last 6 months * Ludwig stage 1-3 for women * If patient has a history of use of topical minoxidil and/or systemic spironolactone for alopecia for at least three consecutive months, then a 3 month washout is required prior to start of treatment * Completed informed consent form Exclusion Criteria: * Patients who are pregnant or breastfeeding * History of hair transplantation * Use of any cosmetic product aimed at improving or correcting the signs of hair loss within 2weeks prior to screening. Note: patients are not permitted to use any hair loss products during the study. * An active scalp dermatologic condition (e.g. alopecia areata, scalp psoriasis), scalp skin cancer (e.g. BCC, SCC), a pre-existing condition with sequelae on the scalp (e.g. scarring alopecia) or acute infection. * Hereditary or acquired hematologic/coagulation disorders such as: platelet dysfunction syndrome, critical thrombocytopenia (platelet count \<150,000 p…